Background/Aim: Thrombopoietin receptor agonists (romiplostim and eltrombopag) have recently been licensed for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) with an insufficient response to corticosteroids, immunoglobulins or splenectomy. In the present case series, we present 4 nonresponding patients with chronic ITP who achieved maintenance of complete response (CR) for a period of at least 6 months on eltrombopag treatment administered in a modified regimen of 25 mg for 2, 3 or 5 days a week. Methods: The present study is a retrospective, nonconsecutive case series of 4 eltrombopag-treated patients with chronic ITP. Secondary ITP had been excluded in each patient, first-line therapy had failed and splenectomy had been refused. Furthermore, each patient was treated with eltrombopag, which resulted in a CR for a mean of 2 months. Consequently, decreased eltrombopag dosages have been able to maintain long-term CR. Results/Conclusion: Despite the low quality of evidence, our study results support the use of reduced-dose eltrombopag as a maintenance therapy after achieving CR. It seems a very promising strategy for the effective maintenance of response, improving health-related quality of life, lowering costs and possibly improving the safety in the treatment of ITP.

1.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2393.
2.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.
3.
Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S: Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13.
4.
Vlachaki E, Papageorgiou V, Klonizakis F, Spandonidou M, Chisan S, Vetsiou E, Ioannidou E: Total remission of severe immune thrombocytopenia after short term treatment with romiplostim. Hematol Rep 2011;3:e20.
5.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JTM, Bourgeois E, Guthrie TH, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL: Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403.
6.
Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M: Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-648.
7.
Garnock-Jones KP, Keam SJ: Eltrombopag. Drugs 2009;69:567-576.
8.
Eltrombopag: drug information (accessed Aug 1, 2013). http://www.uptodate.com/contents/eltrombopag-drug-information?source=related_link.
9.
Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL: Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739-4741.
10.
Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL: AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-1681.
11.
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB: Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393-402.
12.
Cheng G: Eltrombopag for the treatment of immune thrombocytopenia. Expert Rev Hematol 2011;4:261-269.
13.
Siegal D, Crowther M, Cuker A: Thrombopoietin receptor agonists in primary immune thrombocytopenia. Semin Hematol 2013;50:S18-S21.
14.
Ghadaki B, Nazi I, Kelton JG, Arnold DM: Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013;53:2807-2812.
15.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ: International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
16.
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study with Eltrombopag (accessed Aug 1, 2013). ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT00370331.
17.
EXTEND (Eltrombopag Extended Dosing Study) (accessed Aug 1, 2013). Clinical Trials.gov. http://clinicaltrials.gov/show/NCT00351468.
18.
Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A: Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537-545.
19.
Neunert CE: Current management of immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2013;2013:276-282.
20.
Nørgaard M: Thrombosis in patients with primary chronic immune thrombocytopenia. Thromb Res 2012;130(suppl):S74-S75.
21.
Catalá-López F, Corrales I, Martín-Serrano G, Tobías A, Calvo G: Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Med Clin (Barc) 2012;139:421-429.
22.
Sarpatwari A, Bennett D, Logie JW, Shukla A, Beach KJ, Newland AC, Sanderson S, Provan D: Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010;95:1167-1175.
23.
WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects (accessed Mar 19, 2012). http://www.wma.net/en/30publications/10policies/b3/index.html.
24.
Erickson-Miller CL, DeLorme E, Tian S-S, Hopson CB, Stark K, Giampa L, Valoret I, Duffy KJ, Luengo JL, Rosen J, Miller SG, Dillon SB, Lamb P: Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005;33:85-93.
25.
Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL: Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-2171.
26.
Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, Ninomiya H, Kosugi H, Nomura S, Ozaki K, Ikeda Y, Hattori T, Katsura K, Kanakura Y: A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012;10:799-806.
27.
Katsutani S, Tomiyama Y, Kimura A, Miyakawa Y, Okamoto S, Okoshi Y, Ninomiya H, Kosugi H, Ishii K, Ikeda Y, Hattori T, Katsura K, Kanakura Y: Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Hematol 2013;3:323-330.
28.
Ghanima W, Junker P, Hasselbalch HC, Boiocchi L, Geyer JT, Feng X, Gudbrandsdottir S, Orazi A, Bussel JB: Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 2011;155:248-255.
29.
Brynes R, Orazi A, Verma S, Brainsky A, Bailey C, Bakshii K: Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia (ITP) treated with eltrombopag-data from the EXTEND study (abstract 528). ASH Annual Meeting Abstracts, 2011, p 118.
30.
Basciano PA, Bussel JB: Thrombopoietin-receptor agonists. Curr Opin Hematol 2012;19:392-398.
31.
Khalafallah A, Rahman Z, Ogden K, Hannan T: Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia. Mediterr J Hematol Infect Dis 2012;4:e2012003.
32.
Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D: Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 2011;51:842-856.
33.
Shida Y, Takahashi N, Nohda S, Hirama T: Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Jpn J Clin Pharmacol Ther 2011;42:11-20.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.